Objective To determine long-term cardiovascular risk after TIA and to identify the factors associated with increased risk.
In recent years, early recurrence after TIA has decreased from up to 20% to 3.7% as a result of the implementation of secondary stroke prevention efforts such as immediate initiation of antiplatelet drugs or urgent revascularization. 1 Moreover, the use of clinical scores (mainly ABCD, ABCD2, and ABCD3-I) [2] [3] [4] has improved the stratification of early TIA recurrence (within 3 months). Although this risk is now well studied, the long-term vascular stroke risk in stable patients with a TIA is not well described.
The aim of the present study was to determine the long-term risk of developing a stroke or nonstroke vascular event beyond the first 3 months after TIA and to identify the factors associated with an increased risk.
Methods

Participants
Hospital del Mar is a tertiary stroke center with an on-call neurologist and a stroke unit, as well as capabilities for systemic thrombolysis and neurovascular interventions. It is the only hospital in its catchment area, which comprises the 330,000 inhabitants of 3 of the 10 city districts of Barcelona, that can provide urgent imaging studies in patients with TIA as recommended. A prospective observational registry was designed, including all patients with TIA evaluated in the emergency room of our center from January 2006 to January 2016. TIA was defined according to the World Health Organization criteria as rapidly developing clinical symptoms and/or signs of focal loss of cerebral function with reversal symptoms within 24 hours (classic criteria) 5 with no apparent cause other than of vascular origin. 6 All patients with suspect acute neurologic symptoms were directly evaluated by a neurologist trained in vascular pathologies who determined the nature of the symptoms and made the final diagnosis. If patients had fully recovered from symptoms on arrival to hospital, they, their family members, or other caregivers were interviewed to determine the precise neurologic symptoms and their duration. Patients with doubtful symptoms, alternative nonvascular origin of symptoms, or a final diagnosis of TIA mimic (n = 23) were not included in this study. Other exclusion criteria were residence outside the hospital catchment area because of the difficulty of long-term follow-up (n = 26) and absence of informed consent to participate (n = 3). The hospital follows patient care methods and secondary prevention measures according to current European and American guidelines. 7 
Endpoint
The methodology has been described in depth in a previous study. 8 The study endpoint was presentation with a first new vascular event (NVE) >3 months after TIA onset, defined according to the Reduction of Atherothrombosis for Continued Health Registry (REACH) study criteria: vascular death, nonfatal stroke, nonfatal myocardial infarction, or hospitalization due to an atherothrombotic event, including vascular interventions. 9 We did not include in this analysis early recurrences (96 patients, 95.8% with stroke) or interventions that occurred within 3 months of TIA onset because the present study focused on long-term risk in stable patients. Of 683 patients with TIA, 7 patients were excluded because of death (n = 5) or loss of contact (n = 2) within first 3 months of follow-up (figure e-1, flowchart, http://links.lww.com/ WNL/A139).
Follow-up consisted of a clinic visit with a vascular-trained neurologist at 3 months after TIA (start of follow-up) and then, at the physician's discretion, at a clinic appointment and/or telephone contact every 3 to 6 months thereafter. Follow-up lasted until study conclusion (June 1, 2017). We reviewed all patient events, death records, electronic medical records, and hospital admissions records and consulted the primary care physician before considering patients lost to follow-up. For all NVEs, we compiled from medical records all tests, procedures, and events certified by a neurologist, cardiologist, or vascular surgeon (in case of cardiac or peripheral events). A member of our research team confirmed every event, contacting the attending doctor when necessary. 10 : large artery atherosclerosis (LAA), small artery disease, cardioaortic embolism (CE), undetermined causes (unclassified strokes, >1 apparent mechanism), and other (infrequent) causes. We applied the small artery disease classification to patients with no evidence of Glossary CE = cardioaortic embolism; CI = confidence interval; HR = hazard ratio; LAA = large artery atherosclerosis; NVE = new vascular event; REACH = Reduction of Atherothrombosis for Continued Health Registry; SSS-TOAST = Stop Stroke Study Trial of Org 10172 in Acute Stroke Treatment. atherothrombotic or cardioembolic TIA who reported classic lacunar syndrome (pure motor, pure sensory, and sensorimotor syndrome involving at least 2 of 3 specific body parts [face, arm, and leg]) and ataxic hemiparesis or dysarthriaclumsy hand syndrome. 11 We analyzed clinical variables extracted from ABCD2 2 score criteria, with a total score of 7 points: speech impairment without weakness = 1 point or with weakness = 2 points; duration of symptoms 10 to 59 minutes = 1 point or ≥60 minutes = 2 points; age ≥60 years = 1 point; initial hypertension >140 mm Hg (systolic) and/or ≥90 mm Hg (diastolic) = 1 point; and diabetes mellitus = 1 point. We also registered previous TIA, defined as a TIA in the 7 days preceding the index TIA. Emergency room protocols determined the presence of acute infarction by CT in all patients, as shown by signs of acute ischemic changes in radiologic studies, but images for 24 patients were not available for analysis. About half of the population (52.8%, n = 357) also had magnetic resonance studies. A trained radiologist with access to clinical information but blinded to patient outcomes analyzed all images.
Measures
Standard protocol approvals, registrations, and patient consent The local ethics committee approved the TIA registry. We obtained written informed consent from all participants or their designated representative.
Statistical analysis
Assuming 10% losses to follow-up and accepting an α risk of 0.05 and a β risk <0.05 in a 2-sided contrast, the study required a sample size of 96 patients with recurrence and 480 controls to detect a minimum relative risk of 2 with a recurrence rate of 0.2 in the control group. We present data as frequencies and percentages.
We used Kaplan-Meier log rank to perform univariate survival analysis for an NVE and to describe variables. We calculated the relative average rate (NVEs per patient-year) as the number of events found during follow-up divided by the number of years at-risk patients were followed up. The ABCD2 risk score was stratified with well-validated reference values: high (6-7 points), medium (4-5 points), and low (0-3 points) risk. Reference subgroups were those with duration of symptoms <10 minutes, a low ABCD2 score (0-3), and the TIA subtype with the lowest percentage of events (lacunar TIA). We used Cox regression survival analysis to estimate the multivariate hazard ratio (HR) with 95% confidence interval (CI) for an NVE. We adjusted all multivariate models by those variables that achieved significance in univariate analysis and considered 2-sided values of p < 0.05 significant.
Results
A total of 676 patients completed the follow-up to June 2017; 116 cases were censored: 20 discharged home outside the hospital area, 5 lost for unknown reasons, and 91 deaths due to nonvascular causes (figure e-1, http://links.lww.com/ WNL/A139). An NVE was detected in 173 patients (25.6%); 40 patients had an NVE within the first year (5.9%) of followup (figure 1). Mean follow-up was 48.8 ± 32.7 months but differed significantly (p < 0.001) between patients with no Types of NVE and etiologic subgroups Event distribution by type (stroke vs nonstroke p = 0.84) was nonsignificant (p = 0.072): (1) vascular deaths (n = 37, 5.5% of the patient cohort), 10 due to fatal stroke disease (4 hemorrhagic), 2 to fatal myocardial infarction, and 18 to other cardiovascular deaths, as defined by REACH (3 other cardiac origin, 3 vascular or limb infarction origin, and 12 sudden death or death without definite nonvascular cause); (2) nonfatal strokes (n = 60, 8.9%), 2 hemorrhagic; (3) nonfatal myocardial infarctions (n = 21, 3.1%); and (4) hospitalizations for atherothrombotic events or vascular interventions (n = 55, 5.3%), 18 for TIA, 14 for coronary artery disease, and 12 for peripheral artery disease. Of these 173 patients, 93 (13.8%) had cerebrovascular events (fatal stroke, nonfatal stroke) and were hospitalized.
Baseline characteristics and predictors of NVE The mean age was 71.7 ± 13.7 years and was not related to NVE (p = 0.323). Other baseline characteristics and their relationship to NVE in univariate analysis (sex, vascular risk factors, and previous vascular events) are described in table 1. We found associations between NVE and male sex, arterial hypertension, diabetes mellitus, and previous vascular disease. Table 2 shows the relationship between etiologic subgroup of TIA and NVE occurrence. The small artery disease subgroup had the lowest NVE risk but a greater percentage of stroke events, while the LAA and CE groups had the highest NVE risk, with a slightly higher percentage of nonstroke events. Table 3 shows univariate analysis of NVEs related to clinical and radiologic data. We found associations between NVE risk and duration of symptoms, clinical features, and signs of acute infarction. Multivariate Cox analysis showed independent associations of NVE risk with etiologic subgroups, signs of acute infarction, and duration of symptoms (table 4). ABCD2 risk score was associated with NVE in univariate analysis as follows: moderate risk, HR = 1.5 (95% CI 1-2.26); and high risk, HR = 2.46 (95% CI 1.54-3.93) (figure e-2, http://links.lww.com/WNL/A139). Finally, multivariate analysis (adjusted by previous factors) found an independent association only with a high ABCD2 risk score (HR 1.89, 95% CI 1.08-3.31).
Discussion
To the best of our knowledge, this TIA registry offers the longest follow-up, with cerebrovascular and noncerebrovascular 12 Regarding the number of NVEs within 1 year of follow-up, our results agree with previous studies in our population 13 and with a more recent multicenter study of a cohort of 4,789 patients that showed a cardiovascular risk of 6.2% at 1-year follow-up. 1 In our study, protocols were similar: urgent management in specialized units, immediate implementation of imaging studies, and rapid treatment with stroke prevention strategies.
Most studies evaluating vascular risk after TIA have focused on early recurrence; very few, with a limited number of patients, have studied the long-term vascular risk after TIA. [14] [15] [16] [17] Heterogeneous data have been reported, depending on study design and TIA etiologies. [14] [15] [16] [17] Few studies have included noncerebrovascular events in their patient follow-up, and no factors that stratify long-term risk of vascular events in these patients have been described. 18 A 2009 study of TIA and stroke has shown a higher acute risk of stroke recurrence, decreasing over a 10-year maximum follow-up, whereas the risk of coronary events remains constant. 19 Our observations regarding NVE risk after TIA are at the lower end of the range described by previous studies (17.4%-41.3%) at 4 or 5 years. In our data, cumulative NVE risk remained constant over the follow-up period, with similar trends for stroke and nonstroke events beyond 3 months after TIA.
The strongest relationship in our series was with stroke subtype. We applied the recently described SSS-TOAST classification and found that patients with LAA, CE, and undetermined subtype had a higher vascular risk than those with small vessel disease etiology, with the highest HR found in the LAA subgroup. The relationship among TIA subtype, early risk of recurrence after TIA, 1, 20 and NVE after stroke 8 has previously been described. In our study, LAA TIAs were the main established predictor of subsequent stroke in longterm follow-up after TIA despite preventive treatments.
4,21
Our results underline the importance of developing new preventive strategies to lower the long-term vascular risk in these high-risk patients. Moreover, we emphasize the importance of completing a vascular study and correctly classifying the stroke etiology, given the prognostic implications of the etiologic subtype. The subgroup of patients with small artery disease had a higher percentage of stroke than nonstroke events, while patients in the CE and LAA subgroups had very similar risk but a higher percentage of nonstroke events. This finding distinguishes patients with small artery disease from those with all other TIA etiologies in that many of them have no atherosclerosis or related cardiopathologies and cardiovascular recurrences are related to the cerebral small artery pathology itself. Previous studies have described an increased risk of stroke recurrence in patients with a longer duration of symptoms, the presence of specific clinical features, previous vascular cerebral pathology, infarctions on neuroimaging, and several vascular risk factors. 1, 13, 16, 22 Furthermore, we detected a univariate relationship between several of these factors and NVE risk; however, only duration of symptoms and signs of acute infarction remained independently associated with NVEs.
Although risk scores were originally designed to predict shortterm recurrence after TIA, few studies have reported the predictive value of the ABCD2 score for long-term stroke recurrence after TIA. 16, 23 Thus, only 1 study in a small cohort has described the capacity of ABCD2 to predict the risk of NVEs (both cerebrovascular and noncerebrovascular). 16 Our study showed that the punctuation of ABCD2 score stratified in high (6-7 points), medium (4-5 points), and low (0-3 points) risk is useful to identify NVE risk after TIA in longterm follow-up, although the reason why it is able to predict the risk of noncerebrovascular events remains elusive. Moreover, in the analysis of NVE risk related to the individual component of the ABCD2 score, we found that only the duration of symptoms was independently associated with an NVE; classic cardiovascular risk factors such as hypertension or diabetes mellitus were not.
Our study has several limitations. Participants were recruited from patients in an emergency room at a single urban hospital and therefore may have characteristics that are not representative of other populations. The patients were relatively older and had high noncerebrovascular mortality over the course of a prolonged follow-up. Resonance imaging, which has greater sensitivity to assess acute infarction than CT, was available for only half of the patients. Nonetheless, the detection of acute infarction was independently associated with NVEs in our series. This underlines the known importance of detecting acute ischemic lesions in patients to identify early recurrence risk and extends it to longer-term follow-up.
Our results suggest that etiology subgroup was the main factor determining high long-term risk of vascular events in patients with TIA. LAA carried the highest vascular risk, both nonstroke and stroke events, followed by CE.
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